ClinicalTrials.gg
Not yet recruitingNCT07941778ESI-PMRUpdated Nov 17, 2026

Ivarmacitinib Treat PMR

A Phase 2/3 interventional study of Ivarmacitinib and Prednisone in Polymyalgia Rheumatica (PMR), sponsored by Zhejiang University. Not yet recruiting at 6 sites in China. Open to participants aged 50 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Zhejiang University · Phase 2/3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
50 Years to 88 Years
Sex
All
01

Study summary

To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.

Read the detailed description

PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.

Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.

02

Conditions studied

  • Polymyalgia Rheumatica (PMR)

Browse trials for

Keywords

  • JAK1 inhibitor
  • steroids
  • Polymyalgia rheumatica
03

In context

Polymyalgia Rheumatica

68 studies on the registry are indexed under Polymyalgia Rheumatica; 22 are open to participants now.

This study's planned enrollment of 144 is above the median of 66 across 39 interventional studies indexed under Polymyalgia Rheumatica.

Browse Polymyalgia Rheumatica studies →

Lead sponsor

Zhejiang University is the lead sponsor of 357 studies on the registry; 167 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who fulfilled the 2012ACR/EULAR criteria for PMR;
  2. Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
  3. Adults age 50-88, Weight 45-85Kg,
  4. ESR>40mm/h or CRP >50mg/L(5mg/dl),
  5. .

Exclusion criteria

Exclusion Criteria:

  1. Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
  2. Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
  3. Patients with severe osteoarthritis,
  4. Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
  5. virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, infection,
  6. Patients with abnormal liver function (/AST 2 times higher); Moderate to severe renal impairment ( \<60); hyperlipidemia not improved by lipid-lowering drugs,
  7. Pregnant or lactating women,
  8. Patients with a history of who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
  9. Patients with previous visual field disorder or single eye dysfunction, cataract patients,
  10. Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
  11. For patients with abnormal blood routine, lymphocytes \<500/mm3 or ANC \<1000/mm3 or HGB \< 90g/L,
  12. Patients with active bleeding and peptic ulcer,
  13. Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
  14. Those who have participated in other drug clinical trials within 4 weeks
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Ivarmacitinib

    Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

    Drug: Ivarmacitinib

  • Active comparator
    Prednisone

    Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose.

    Drug: Prednisone

Interventions

  • DrugIvarmacitinib

    Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks.

  • DrugPrednisone

    The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose.

06

What researchers measure

Primary outcomes

  1. Proportion of patients in remission at weeks 24

    Proportion of patients in remission at weeks 24

    Time frame: at weeks 24

Secondary outcomes

  1. Proportion of patients in remission at weeks 52

    Proportion of patients in remission at weeks 52

    Time frame: at weeks 52

  2. PMR-AS score at weeks 24

    PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+\[morning stiffness (min) x0.1\]+ EUL (0-3).

    Time frame: at weeks 24

  3. CRP at weeks 24

    CRP at weeks 24

    Time frame: at weeks 24

  4. ESR at weeks 24

    ESR at weeks 24

    Time frame: at weeks 24

  5. Relapse rate within 52 weeks

    Relapse rate within 52 weeks

    Time frame: within 52 weeks

  6. Relapse times within 52 weeks

    Relapse times within 52 weeks

    Time frame: within 52 weeks

  7. Cumulative dose of prednisone within 52 weeks

    Cumulative dose of prednisone within 52 weeks

    Time frame: within 52 weeks

  8. Cumulative dose of MTX within 52 weeks

    Cumulative dose of MTX within 52 weeks

    Time frame: within 52 weeks

07

Study locations

6 sites
08

References and documents

Publications

  • Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1796. Epub 2024 Oct 28. PubMed 39470163 ↗
  • Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L, Xu X, Wu R, Liu X, Zhang J, Xu S, Zhu P, Chen H, Wang X, Lin C, Lin J, Zhan F, Wei H, Huang Q, Liu H, Ma X, Shi G, Lu Y, Geng X, Jiang Z, Zhang N, Tang K, Zhang R, Zhao Y, Xue L, Song S, Shi X, Zhang Z, Liu P, Wang H, Li Z. Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. Arthritis Rheumatol. 2025 Nov;77(11):1512-1523. doi: 10.1002/art.43238. Epub 2025 Aug 5. PubMed 40509748 ↗
  • Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D. Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. Front Pharmacol. 2025 Nov 20;16:1710434. doi: 10.3389/fphar.2025.1710434. eCollection 2025. PubMed 41357869 ↗
  • Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025 Feb;84(2):188-200. doi: 10.1136/ard-2024-226385. Epub 2025 Jan 3. PubMed 39919893 ↗
  • Ma X, Yang F, Wu J, Xu B, Jiang M, Sun Y, Sun C, Yu Y, Xu D, Xiao L, Ren C, Chen C, Ye Z, Liang J, Lin J, Chen W. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023 Jun 29;20(6):e1004249. doi: 10.1371/journal.pmed.1004249. eCollection 2023 Jun. PubMed 37384596 ↗
  • Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459. PubMed 36125471 ↗
  • Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444. PubMed 27299619 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2028, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941778
Responsible party
Weiqian Chen (Doctor, Zhejiang University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Weiqian Chen Dr. Chen, Doctor
Contact
cwq678@zju.edu.cn
860571-87233418
Xinxin Han Dr. Han, Doctor
Contact
hxx1992@126.com
860571-87233418
Jin Lin, Prof.
study director · First Affiliated Hospital of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion